Comments
Celgene's pomalidomide improves survival in multiple myeloma
20.11.2012. | (Reuters) - Celgene Corp's experimental cancer drug pomalidomide significantly improved survival in patients with multiple myeloma who had failed other therapies, according to a summary of data to be presented at a medical meeting next month....
